The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.

The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.

The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.